1. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis. Issue 1 (January 2014) Authors: Sheridan, James P; Robinson, Randy R; Rose, John W Journal: Expert review of clinical pharmacology Issue: Volume 7:Issue 1(2014) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Issue 1 (21st December 2022) Authors: Carneiro, Benedito A; Papadopoulos, Kyriakos P; Strickler, John H; Lassman, Andrew B; Waqar, Saiama N; Chae, Young Kwang; Patel, Jyoti D; Shacham-Shmueli, Einat; Kelly, Karen; Khasraw, Mustafa; Bestvina, Christine M; Merrell, Ryan; Huang, Kevin; Atluri, Harisha; Ansell, Peter; Li, Rachel; Jin, Ja... Journal: Neuro-oncology advances Issue: Volume 5:Issue 1(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗